Veterinary Defibrillators Market: as the American Veterinary Medical Association's revised CPR guidelines explicitly frame defibrillation as a vital protocol component rather than optional specialist equipment, general veterinary practice owners face a documented standard of care they did not have before, converting what many previously treated as a discretionary capital purchase into a defined institutional expectation with genuine referral and liability consequences for practices that choose not to acquire it.

The global veterinary defibrillators market size was USD 75.4 Million in 2025 and is expected to register a revenue CAGR of 5.5% during the forecast period. Market revenue growth is driven by factors such as rising prevalence of cardiac arrhythmias in dogs and cats expanding the clinical population requiring defibrillation capability, updated professional society CPR guidelines establishing species-specific defibrillation protocols as a documented standard of care, and portable AED adoption at small and mid-size veterinary practices extending defibrillation capability beyond specialist referral hospitals. The first driving factor is rising prevalence of cardiac arrhythmias in dogs and cats, which directly expands the clinical population requiring defibrillation capability across general practice and specialist veterinary settings. Automated external defibrillators account for a substantial share of total 2025 market revenue, reflecting this category's centrality to the broadest range of general veterinary practice adoption. The second driving factor is updated professional society CPR guidelines, which establish species-specific defibrillation protocols as a documented standard of care that procurement committees and practice owners can reference. The third driving factor is portable AED adoption at small and mid-size veterinary practices, which extends defibrillation capability beyond specialist referral hospitals into general practice settings previously without this equipment. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single professional society CPR guideline revision converts a clinical preference decision into a documented reference standard, which lets practice owners and procurement committees justify capital equipment acquisition against an established professional benchmark rather than relying on individual veterinarian judgement or specialist referral relationships alone. Because a general practice veterinary owner previously evaluating whether to acquire a defibrillator could reasonably conclude that it was specialist equipment better left to referral centres, the explicit inclusion of defibrillation as a vital CPR protocol component in revised guidelines creates a documented standard of care that shifts this calculus, converting a discretionary purchase decision into one with genuine institutional and liability implications for practices that decline to acquire the equipment. As a result, demand and revenue share are concentrating around portable, general-practice-appropriate defibrillator platforms specifically designed for veterinary practices without dedicated cardiology specialty staff, and the forecast reflects this guideline-driven adoption expansion as a distinct driver of the market's broadening addressable practice base. For instance, in July 2024, the American Veterinary Medical Association published updated CPR guidelines for cats and dogs establishing species-specific defibrillation protocols, explicitly abandoning the prior one-size-fits-all approach and emphasising defibrillation as a vital component of the CPR protocol rather than optional specialist equipment. These are some of the key factors driving revenue growth of the market.

Because effective defibrillation requires specific clinical training in species-appropriate energy dosing and rhythm interpretation that general practice veterinary staff may not have received as part of standard veterinary education, even a general practice that acquires defibrillation equipment faces a genuine staff training investment before the equipment can be used confidently in an actual cardiac emergency.

Capital budget constraints at smaller general practice veterinary clinics competing against other diagnostic and treatment equipment priorities are a second constraint, since a defibrillator competes for limited capital equipment budget against other diagnostic and treatment technology that a general practice may view as more central to its daily case volume, even where the updated CPR guidelines establish defibrillation as a documented standard of care.

Low clinical utilisation frequency relative to equipment cost is a third constraint, since cardiac arrest emergencies requiring defibrillation occur relatively infrequently at any single general veterinary practice, which can make the capital cost harder to justify against measured utilisation compared to equipment used in nearly every patient visit.

These factors substantially limit veterinary defibrillators market growth over the forecast period.

The clearest driver of demand is rising prevalence of cardiac arrhythmias in dogs and cats, which directly expands the clinical population requiring defibrillation capability across general practice and specialist veterinary settings. A companion animal presenting in cardiac arrest or with a life-threatening arrhythmia requires immediate defibrillation capability at the point of care, so this market's baseline demand tracks documented cardiac disease prevalence trends in the companion animal population directly. Automated external defibrillators account for a substantial share of total 2025 market revenue, and in January 2025, Heska Corporation unveiled a portable veterinary defibrillator with integrated real-time monitoring features specifically designed for emergency animal cardiac assessment at general practice settings. The effect on the market is that baseline veterinary defibrillator demand remains structurally tied to companion animal cardiac disease prevalence, providing a demand base independent of any single manufacturer's product strategy. These are some of the key factors driving revenue growth of the market.

The second driver is updated professional society CPR guidelines, which establish species-specific defibrillation protocols as a documented standard of care that procurement committees and practice owners can reference when justifying capital equipment acquisition. A general practice veterinary owner previously evaluating whether defibrillation equipment was necessary for their practice could reasonably conclude it was specialist equipment better left to referral centres, so an explicit professional society guideline emphasising defibrillation as a vital CPR protocol component directly shifts this institutional calculus. In July 2024, the American Veterinary Medical Association published updated CPR guidelines for cats and dogs, establishing species-specific defibrillation protocols and explicitly abandoning the prior one-size-fits-all approach used across veterinary emergency medicine. The effect on the market is that general practice veterinary clinics now face a documented professional standard creating institutional pressure to acquire defibrillation capability or establish clear referral pathways for cardiac emergency patients. These are some of the key factors driving revenue growth of the market.

The AVMA's July 2024 CPR guideline revision is meaningful for the same reason a professional society consensus is meaningful in any device category: it converts a clinical preference decision into a documented reference standard. Before the revision, a general practice veterinary owner could reasonably treat defibrillation as specialist equipment; after it, the same practice faces a documented standard of care with genuine referral and liability implications.

The third driver is portable AED adoption at small and mid-size veterinary practices, which extends defibrillation capability beyond specialist referral hospitals into general practice settings previously without this equipment. A portable, general-practice-appropriate AED design specifically addresses the operational reality that most veterinary practices lack dedicated cardiology specialty staff, so a device engineered for use by general practice veterinarians and technicians without specialist cardiology training directly expands the addressable practice population beyond specialist referral centres. In 2024, Meditech Equipment launched a new AED for combined human and veterinary use, using shared cross-platform manufacturing scale to offer general veterinary practices a more cost-accessible defibrillation option than dedicated veterinary-only platforms. The effect on the market is that defibrillator adoption is expanding beyond specialist referral hospitals into the much larger population of general practice veterinary clinics, particularly following the AVMA's guideline revision establishing broader institutional expectations. These are some of the key factors driving revenue growth of the market.

However, the veterinary defibrillators market faces severe adoption constraints from limited veterinary staff training in defibrillation technique outside specialist emergency and cardiology practices, and capital budget constraints at smaller general practice veterinary clinics competing against other diagnostic and treatment equipment priorities.

Because effective defibrillation requires specific clinical training in species-appropriate energy dosing and rhythm interpretation that general practice veterinary staff may not have received as part of standard veterinary education, even a general practice that acquires defibrillation equipment, including newer portable platforms like Heska's January 2025 launch, faces a genuine staff training investment before the equipment can be used confidently in an actual cardiac emergency.

Capital budget constraints at smaller general practice veterinary clinics competing against other diagnostic and treatment equipment priorities compound this, since a defibrillator competes for limited capital equipment budget against other diagnostic and treatment technology that a general practice may view as more central to its daily case volume, even where the AVMA's updated CPR guidelines establish defibrillation as a documented standard of care.

Low clinical utilisation frequency relative to equipment cost is the third constraint, since cardiac arrest emergencies requiring defibrillation occur relatively infrequently at any single general veterinary practice, which can make the capital cost harder to justify against measured utilisation compared to equipment used in nearly every patient visit.

These factors substantially limit veterinary defibrillators market growth over the forecast period.

Based on product type, the global veterinary defibrillators market is segmented into automated external defibrillators, manual external defibrillators, and combination devices. Automated external defibrillators hold the largest revenue share, because their simplified operation suits the broadest range of general veterinary practice staff without specialist cardiology training, which suits a market where the most broadly deployable device format commands the largest revenue category following the AVMA's guideline-driven general practice adoption expansion. Manual external defibrillators remain the preferred format at specialist referral hospitals with dedicated emergency and cardiology staff. Combination devices are expected to register the fastest revenue growth rate in the global veterinary defibrillators market over the forecast period, driven by Heska's January 2025 launch integrating real-time monitoring with defibrillation capability.

Based on technology, the global veterinary defibrillators market is segmented into biphasic and monophasic waveform defibrillators. Biphasic defibrillators hold the largest revenue share, because biphasic waveform technology demonstrates improved defibrillation efficacy at lower energy levels relative to monophasic alternatives, aligning with the AVMA's species-specific protocol emphasis on appropriate energy dosing. Biphasic defibrillators are also expected to register the fastest revenue growth rate in the global veterinary defibrillators market over the forecast period, driven by continued technology migration away from older monophasic platforms.

Based on animal type, the global veterinary defibrillators market is segmented into small animals, large animals, equine, and exotic and zoo animals. Small animals hold the largest revenue share, reflecting the concentration of companion animal cardiac disease prevalence and the AVMA's cats-and-dogs-specific guideline revision within this population specifically. Exotic and zoo animals are expected to register a moderate revenue growth rate in the global veterinary defibrillators market over the forecast period, reflecting continued specialist zoological and exotic animal medicine practice expansion.

Based on regional analysis, the veterinary defibrillators market in North America accounted for largest revenue share in 2025. The United States leads because the AVMA's July 2024 CPR guideline revision creates the deepest and most institutionally documented adoption pressure globally, and because Heska Corporation, Avante Animal Health, and Digicare Biomedical all maintain significant commercial presence in the US market. Heska's January 2025 portable defibrillator launch specifically reinforces the depth of US-anchored general practice product innovation following the guideline revision. The concentration of AVMA-accredited veterinary teaching hospital activity in the country also means new defibrillation protocol standards typically establish in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent significant national markets within Europe. The result is steady rather than rapid growth, shaped more by national veterinary association protocol adoption timelines than by underlying demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and Japan represent two of the largest national markets within the region, anchored by Mindray's and Shenzhen Comen's Chinese manufacturing base. The region's rapidly expanding companion animal ownership and veterinary specialty infrastructure leaves considerably more room for growth than in the already defibrillator-mature North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with expanding veterinary specialty and emergency care infrastructure driving early defibrillator demand growth, reinforced by Shenzhen Comen's continued Latin American regional resource expansion. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the specialised electronics and battery components that Latin American veterinary defibrillator distributors depend on, an effect expected to run through 2026 and slow veterinary defibrillators adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding veterinary specialty infrastructure and the UAE's regional distribution hubs represent the primary investment centres for veterinary defibrillators adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the veterinary emergency care infrastructure needed to support advanced defibrillation platforms at scale.